The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study
Open accessAbstract
BACKGROUND: Bipolar disorder is a highly recurrent disease and has great impact on the function of patients. Depressive symptoms consist of more than 50% of life time during the illness and may lead to self harm or suicidal behaviors. Little is known about the antidepressant effects of olanzapine, an atypical antipsychotic, as monotherapy despite its indication for preventing manic episodes. In contrast, lamotrigine, a mood stabilizer, has been proven to be effective in preventing depression in patients with bipolar disorder. However, no studies have compared the efficacy between lamotrigine and olanzapine in the maintenance treatment of bipolar disorder. This enriched naturalistic study was implemented to assess the effectiveness of olanzapine and lamotrigine as monotherapy in the prevention of recurrence of bipolar disorder. METHODS: Patients with bipolar disorder in a euthymic state (Young's Mania Rating Scale (YMRS) score <12, and 21-item Hamilton Depression Rating Scale (HAM-D) score <7) for at least two months, having already received either olanzapine or lamotrigine as the maintenance treatment were recruited. The patients maintained with olanzapine (n = 22) were applied to olanzapine group whereas those maintained with lamotrigine (n = 29) were applied to lamotrigine group. They were followed up for 12 months. Differences in the efficacy between olanzapine and lamotrigine in recurrence prevention were analyzed. The Kaplan-Meier method was used to generate time-to-recurrence curves, and differences between the two groups were compared using the log-rank test. RESULTS: Olanzapine had a significantly lower recurrence rate of depressive episodes than lamotrigine (20.0% vs. 57.7%, χ2 = 6.62, p = .010). However, olanzapine and lamotrigine had similar mania (15.0% vs. 0%, χ2 = 4.17, p = .075, Fisher's exact test) and any mood episode (35.0% vs. 57.7%, χ2 = 2.33, p = .127) recurrence rates. Olanzapine was significantly superior to lamotrigine in the time to recurrence of depressive episodes (χ2 = 4.55, df = 1, p = .033), but there was no difference in the time to recurrence of any mood episode (χ2 = 1.68, df = 1, p = .195). CONCLUSIONS: This prospective naturalistic study suggests that olanzapine is more effective than lamotrigine in the prevention of depressive episodes in patients with bipolar disorder. Future large-scale randomized studies are warranted to validate our results. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT01864551.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are insufficient data to make a recommendation regarding olanzapine.506”
From Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [506]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Relapse and impairment in bipolar disorder
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1635 · Cited by 762
McElroy, S. L., Altshuler, L. L., Suppes, T., Keck, P. E., Frye, M. A., Denicoff, K. D., Nolen, W. A., Kupka, R. W., Leverich, G. S., Rochussen, J. R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.420 · Cited by 693
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689 · cited 4×
“Olanzapine has also been found to be effective in decreasing concurrent anxiety symptoms in patients with bipolar disorder [27,28] that are considered to be a predictor of depressive recurrence [11], and also to be associated with poor treatment response and worse symptom severity [29-31].”
BackgroundInfluentialBowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678 · cited 1×
“It has been reported that lamotrigine is not superior to lithium in the prevention of bipolar depression [39], and also that lithium is not indicated for the prevention of bipolar depression compared to a placebo [50].”
BackgroundBowden, C. L. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.392 · Cited by 658
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0906 · Cited by 635
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Leon, A. C., Solomon, D. A., Coryell, W., Maser, J. D., & Keller, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1322 · Cited by 577 · cited 2×
“Depressive symptoms and episodes dominate the course of illness [6] and may lead to social and family dysfunction, repeated hospitalizations and even suicidal behaviour [7,8].”
BackgroundOutcome in Mania: A 4-Year Prospective Follow-up of 75 Patients Utilizing Survival Analysis
Tohen, M. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240026005 · Cited by 532
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Meta-Analysis of the Risk of Subsequent Mood Episodes in Bipolar Disorder
Raduà, J., Grunze, H., & Amann, B. L. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000449417 · Cited by 94
Besag, F., Vasey, M. J., Sharma, A., & Lam, I. C. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211045870 · Cited by 62
Wąsik, A., Białoń, M., Żarnowska, M., & Antkiewicz‐Michaluk, L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.002 · Cited by 29
Heptakis(2,6-di-O-methyl)-β-CD as a host of olanzapine: Experimental and computational study
Yousef, F. O., Ghanem, R. A., El‐Barghouthi, M. I., Abu-Shattal, E. D., Al‐Sa'doni, H. H., & Bodoor, K. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134812 · Cited by 9
Metadata
- Authors
- Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B.
- Affiliations
- Tri-Service General Hospital (TW)
- National Defense Medical Center (TW)
- Corresponding author
- Yeh, Chin-Bin
- Venue
- BMC Psychiatry
- Published
- 2014-05-19
- Volume
- 14
- Issue
- 1
- Pages
- 145-145
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC4035822
- OpenAlex
- W2072748137
- Cited by
- 9
- References
- 55
- Citations by year
- 2022: 2 · 2021: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2015: 2
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Tri-Service General Hospital
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar depression, olanzapine, lamotrigine, recurrence prevention, antidepressant monotherapy, atypical antipsychotics, mood stabilizers, time to recurrence, euthymic bipolar patients, treatment efficacy comparison, suicide risk, suicidal behavior, self-harm
- MeSH terms
- Olanzapine, Lamotrigine, Adult, Antidepressive Agents, Benzodiazepines, Bipolar Disorder, Depressive Disorder, Female, Humans, Male, Middle Aged, Prospective Studies, Antipsychotic Agents, Triazines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. https://app.cochat.ai/papers/10.1186/1471-244x-14-145
- The paper
- Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B. (2014). Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.